ANGPTL3 and type 2 diabetes mellitus: ISIS-703802, a designed ANGPTL3 inhibitor, recently completed phase II trials in subjects with hypertriglyceridemia, T2DM, and non-alcoholic fatty liver disease (Jiang et al., 2019).